Management of Infant Gastroesophageal Reflux Disease (GERD)
Introduction to GERD Management
- The American Academy of Pediatrics recommends dietary modification as the initial management strategy for infants with GERD symptoms, before considering pharmacologic therapy, to prioritize morbidity and quality of life outcomes while avoiding unnecessary medication risks 1, 2, 3, 4.
Dietary Modification
- An extensively hydrolyzed protein or amino acid-based formula is appropriate for formula-fed infants with GERD symptoms as the first-line intervention after conservative measures have failed, addressing potential cow's milk protein allergy, which can present identically to GERD in infants 1, 2, 3, 4.
- The trial of extensively hydrolyzed protein or amino acid-based formula should last 2-4 weeks to adequately assess response 1, 2, 3.
Rationale Against Acid Suppressive Therapy
- Acid suppressive therapy (H2 antagonists or PPIs) should NOT be used solely for infant GERD symptoms without first attempting dietary modification, due to significant risks including increased risk of community-acquired pneumonia, gastroenteritis, candidemia, and necrotizing enterocolitis in preterm infants 1, 2, 3, 4, 5.
- H2 antagonists develop tachyphylaxis within 6 weeks and may increase risk of liver disease and gynecomastia 1, 2, 3, 4.
Clinical Context and Treatment Algorithm
- Infants presenting with typical GERD symptoms (spitting up, post-feeding irritability, back arching, sleep disturbance) without warning signs (bilious vomiting, GI bleeding, forceful vomiting, fever, or poor weight gain) should first undergo a 2-4 week trial of extensively hydrolyzed protein or amino acid-based formula 1, 2, 4.
- If symptoms persist after adequate formula trial and infant has clear signs of pathological GERD, further evaluation per GERD guidelines and possible trial of acid suppression (PPI preferred over H2RA if needed) for 4-8 weeks maximum without re-evaluation should be considered 5.